Analytical Data
-
基因名
IpaD
- Application
-
别名
36KDA membrane antigen
-
种属
Shigella flexneri
-
表达系统
E. coli
-
标签
N- His-SUMO & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P18013
-
表达区间
1-332aa
-
分子量
56.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IpaD is an essential protein derived from the intracellular bacterium Shigella flexneri, which is a significant causative agent of bacterial dysentery in humans. Research surrounding IpaD has gained prominence due to its critical role in the type III secretion system (T3SS), a sophisticated molecular syringe utilized by Shigella to inject effector proteins into host cells, facilitating bacterial invasion and immune evasion. Understanding the structure and function of IpaD is vital, as it acts as a key regulator in T3SS assembly and effector translocation. The protein has garnered attention for its potential as a vaccine candidate and for its utility in developing novel therapeutic strategies against Shigella infections. Studies have revealed that IpaD interacts with various host cell components, contributing to the pathogenicity of Shigella. Furthermore, the exploration of IpaD re-combinantly expressed in different systems offers insights into its immunogenic properties and biological functionalities. This research could pave the way for innovative interventions that target the T3SS, ultimately leading to enhanced prevention and treatment options for shigellosis and related diseases. As antibiotic resistance continues to rise, the significance of non-antibiotic therapeutics derived from an understanding of IpaD and its mechanisms becomes increasingly critical.
